PD 153035
PD153035 HCl
CAS: 183322-45-4
Molecular Formula: C16H14BrN3O2.HCl
PD 153035 - Names and Identifiers
PD 153035 - Physico-chemical Properties
| Molecular Formula | C16H14BrN3O2.HCl |
| Melting Point | 265°C(lit.) |
| Solubility | DMSO: soluble2mg/mL, clear (warmed) |
| Appearance | powder |
| Color | white to beige |
| Storage Condition | Sealed in dry,Room Temperature |
| MDL | MFCD01074805 |
| Use | PD153035 HCl is a potent, specific EGFR inhibitor with Ki and IC50 of 5.2 pM and 29 pM, respectively; it has little effect on PGDFR, FGFR, CSF-1,InsR and Src. |
| In vitro study | PD153035 inhibited A- 431 human squamous cell carcinoma-associated epidermal growth factor receptor tyrosine kinase with a Ki of 5.2 pM and an IC50 of 29 pM. Furthermore, PD 153035 effectively and selectively inhibited EGF-induced tyrosine phosphorylation in Swiss 3T3 fibroblasts and A- 431 human squamous cell carcinoma cells with IC50 of 15 nM and 14 nM, respectively. PD153035 acts on human cancer cell lines that overexpress EGF receptor, including A431, Difi, DU145, MDA-MB-468 and ME180 cells to inhibit growth with IC50 of 0.22 μm and 0.3 μm, respectively, 0.4 M, 0.68 M and 0.95 M. PD153035 inhibited nasopharyngeal carcinoma (NPC) cells, including NPC-TW01, NPC-TW04, and HONE1 cell lines, in a dose-dependent manner with IC50 values of 12.9 μm, 9.8 μm, and 18.6 μm, respectively. Recent studies have shown that PD153035 acts on Caco-2 colon cancer cells, abrogating the COX-2 expression induced by PAR(2) activating peptide 2-furanformyl-LIGRLO-NH(2)(2fLI). PD153035 inhibited A- 431 human squamous cell carcinoma-associated epidermal growth factor receptor tyrosine kinase at K I of 5.2 pM and IC50 of 29 pM. And, PD 153035 effectively and selectively inhibited EGF-induced tyrosine phosphorylation in Swiss 3T3 fibroblasts and A- 431 human squamous cell carcinoma cells with IC50 of 15 nM and 14 nM, respectively. PD153035 acts on human cancer cell lines that overexpress EGF receptor, including A431, Difi, DU145, MDA-MB-468 and ME180 cells to inhibit growth with IC50 of 0.22 μm and 0.3 μm, respectively, 0.4 M, 0.68 M and 0.95 M. PD153035 inhibited nasopharyngeal carcinoma (NPC) cells, including NPC-TW01, NPC-TW04, and HONE1 cell lines, in a dose-dependent manner with IC50 values of 12.9 μm, 9.8 μm, and 18.6 μm, respectively. Recent studies have shown that PD153035 acts on Caco-2 colon cancer cells, abrogating the COX-2 expression induced by PAR(2) activating peptide 2-furanformyl-LIGRLO-NH(2)(2fLI). |
| In vivo study | PD153035 inhibited EGF receptor tyrosine kinase activity at a dose of 80 mg/kg in Immunodeficient nude mice bearing A431 human epidermoid carcinoma cell xenografts. PD153035 acts on HFD-fed mice to promote glucose tolerance, insulin sensitivity, and signaling, and to reduce subclinical inflammation. PD153035 at a dose of 80 mg/kg inhibited EGF receptor tyrosine kinase activity in Immunodeficient nude mice bearing transplanted tumor of A431 human epidermoid carcinoma cells. PD153035 acts on HFD-fed mice to promote glucose tolerance, insulin sensitivity, and signaling, and to reduce subclinical inflammation. |
PD 153035 - Risk and Safety
| Hazard Symbols | T - Toxic |
| Risk Codes | R25 - Toxic if swallowed R37/38 - Irritating to respiratory system and skin. R41 - Risk of serious damage to eyes |
| Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S39 - Wear eye / face protection. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) |
| UN IDs | UN 2811 6.1 / PGIII |
| WGK Germany | 3 |
PD 153035 - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.521 ml | 12.605 ml | 25.21 ml |
| 5 mM | 0.504 ml | 2.521 ml | 5.042 ml |
| 10 mM | 0.252 ml | 1.26 ml | 2.521 ml |
| 5 mM | 0.05 ml | 0.252 ml | 0.504 ml |
Last Update：2024-01-02 23:10:35
PD 153035 - Introduction
PD153035 HCl (also known as Gefitinib HCl) is a chemical substance that has the following properties:
1. Appearance: PD153035 HCl is a white crystalline powder.
2. Solubility: PD153035 HCl is soluble in water and organic solvents (such as methanol, ethanol and dimethyl sulfoxide).
3. Use: PD153035 HCl is a clinical anti-tumor drugs, belonging to tyrosine kinase inhibitors. It can block the growth and division of cancer cells by inhibiting the activity of the epidermal growth factor receptor (EGFR).
4. Preparation method: PD153035 HCl preparation method is usually obtained by synthesis or chemical reaction. The specific preparation may involve a corresponding chemical synthesis route.
5. Safety Information: PD153035 HCl in use need to pay attention to the following safety matters:
-May cause eye, skin and respiratory tract irritation. Take protective measures during operation, such as wearing protective glasses, gloves and masks.
-Avoid inhalation or contact with the skin, to ensure that the operation in a well-ventilated environment.
-Before use, read the product manual carefully and follow the correct use and handling methods.
-Comply with laboratory safety procedures and dispose of waste properly.
Please note that PD153035 HCl is a chemical with specific medicinal uses and should only be used in an appropriate laboratory or medical environment. Consult professional medical or chemical personnel before use, and strictly follow relevant regulations and safe operation guidelines.
1. Appearance: PD153035 HCl is a white crystalline powder.
2. Solubility: PD153035 HCl is soluble in water and organic solvents (such as methanol, ethanol and dimethyl sulfoxide).
3. Use: PD153035 HCl is a clinical anti-tumor drugs, belonging to tyrosine kinase inhibitors. It can block the growth and division of cancer cells by inhibiting the activity of the epidermal growth factor receptor (EGFR).
4. Preparation method: PD153035 HCl preparation method is usually obtained by synthesis or chemical reaction. The specific preparation may involve a corresponding chemical synthesis route.
5. Safety Information: PD153035 HCl in use need to pay attention to the following safety matters:
-May cause eye, skin and respiratory tract irritation. Take protective measures during operation, such as wearing protective glasses, gloves and masks.
-Avoid inhalation or contact with the skin, to ensure that the operation in a well-ventilated environment.
-Before use, read the product manual carefully and follow the correct use and handling methods.
-Comply with laboratory safety procedures and dispose of waste properly.
Please note that PD153035 HCl is a chemical with specific medicinal uses and should only be used in an appropriate laboratory or medical environment. Consult professional medical or chemical personnel before use, and strictly follow relevant regulations and safe operation guidelines.
Last Update：2024-04-09 19:05:02
Supplier List
Spot supply
Product Name: PD153035 HCl Visit Supplier Webpage Request for quotationCAS: 183322-45-4
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: PD153035 HCl Visit Supplier Webpage Request for quotationCAS: 183322-45-4
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History